Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:EWTX 18 December 2025 - 30 December 2025

Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX

Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX

Edgewise Therapeutics shares rose 0.2% to $24.68 after a Form 144 filing showed officer Robert Michael Carruthers sold 116,665 shares for about $3.04 million on Dec. 26. The stock traded between $24.40 and $24.92 midday. The sale followed a Dec. 24 update on the company’s Phase 2 trial of EDG-7500 in hypertrophic cardiomyopathy. Biotech stocks broadly traded lower.
30 December 2025
·
Edgewise Therapeutics (EWTX) Stock Today: EDG-7500 Safety Update, Analyst Targets, and What Investors Are Watching Next

Edgewise Therapeutics (EWTX) Stock Today: EDG-7500 Safety Update, Analyst Targets, and What Investors Are Watching Next

Edgewise Therapeutics shares fell 4.7% to around $26.00 Friday after a clinical update on its EDG-7500 program in hypertrophic cardiomyopathy. The company reported no significant safety concerns in interim Phase 2 data, with over 40 participants enrolled and no clinically meaningful drops in ejection fraction. Biotech stocks lagged, with XBI down 1.16% and IBB off 0.86%, while broader indexes traded flat.
26 December 2025
·
Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

Edgewise Therapeutics shares closed at $27.38 on December 24, up 26% after the company reported a favorable interim safety update for its EDG-7500 therapy in hypertrophic cardiomyopathy. Pre-market trading showed the stock at $27.46 as of 8:52 a.m. ET Friday. No clinically meaningful drops in ejection fraction or new atrial fibrillation were seen in the latest trial cohort. Regular U.S. trading resumes at 9:30 a.m. ET.
26 December 2025
···
Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics shares jumped 21% to $26.37 intraday Wednesday after the company reported positive interim safety data for its EDG-7500 therapy in hypertrophic cardiomyopathy. The update showed no clinically meaningful LVEF reductions and no LVEF drops below 50% among 20 patients, with one new-onset atrial fibrillation event disclosed. Over 40 participants have enrolled in Part D of the trial.
24 December 2025
··
Edgewise Therapeutics (EWTX) Stock News Today: What’s Driving the Volatility, Analyst Forecasts, and Key Catalysts (Dec. 22, 2025)

Edgewise Therapeutics (EWTX) Stock News Today: What’s Driving the Volatility, Analyst Forecasts, and Key Catalysts (Dec. 22, 2025)

Edgewise Therapeutics shares swung between $27.77 and $21.18 on Dec. 22, closing at $21.29 with volume over one million. The volatility followed a 20.8% surge on Dec. 19 and mixed analyst commentary, including JPMorgan raising its price target to $34 despite concerns over a $40.67 million quarterly loss.
22 December 2025
··
Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next

Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next

Edgewise Therapeutics shares surged 20.8% to $25.55 on December 19, 2025, trading over 3.1 million shares after a prior decline. No new company press releases or major updates were issued in the past 24–48 hours. The move followed routine equity grant news on December 2 and Q3 results on November 6. Analyst price targets remain above current levels.
21 December 2025
··
Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge

Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge

Edgewise Therapeutics shares surged 20.8% to $25.55 on December 19, 2025, amid heavy trading and technical breakout signals. The move follows recent investor conference appearances and ongoing focus on late-stage neuromuscular and cardiovascular drug programs. As of September 30, the company reported $563.3 million in cash and a Q3 net loss of $40.7 million.
20 December 2025
·
Edgewise Therapeutics (EWTX) Stock News and Forecast: Why Shares Rebounded on Dec. 19, 2025—and What Analysts Are Watching Next

Edgewise Therapeutics (EWTX) Stock News and Forecast: Why Shares Rebounded on Dec. 19, 2025—and What Analysts Are Watching Next

Edgewise Therapeutics shares jumped 8.79% to close at $23.01 on Dec. 19 after a volatile session and recent losses. The move coincided with elevated trading volume and options expiration. The company is advancing therapies for muscular dystrophies and cardiac conditions, with key clinical updates expected in late 2025 and beyond.
19 December 2025
···
Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

Edgewise Therapeutics shares fell 8.8% to $20.35 on Thursday, with no new company news released that day. The stock traded between $20.33 and $22.81 on volume of about 1.25 million shares. EWTX remains 38% below its 52-week high and 92% above its 52-week low. The company’s recent updates include a December stock option grant and a November board appointment.
18 December 2025
··

Stock Market Today

  • UK Stocks Edge Lower Amid Middle East Tensions and Weak Housing Data
    April 9, 2026, 12:37 PM EDT. London's FTSE 100 slipped 0.05% as renewed Iran-US tensions flared following Israeli strikes in Lebanon, leading Iran to block oil tanker passage through the Strait of Hormuz. Danske Bank warned of likely escalation due to persistent ceasefire disputes. UK housing market data showed worsening conditions, with the Royal Institution of Chartered Surveyors reporting a -23% house price balance in March, its weakest since December 2023, dampening prospects for UK-listed housebuilders. RICS and RBC Capital Markets highlighted deteriorating buyer demand and sales expectations amid rising mortgage costs and energy price volatility. On the corporate front, London Stock Exchange Group gained 0.18% after announcing a £900 million share buyback, while British American Tobacco shares fell 1.99% following the appointment of Dragos Constantinescu as CFO effective September 1.

Latest article

SBTi Says Corporate Climate Targets Jumped 40% in 2025 as Asia Closes In on Europe

SBTi Says Corporate Climate Targets Jumped 40% in 2025 as Asia Closes In on Europe

9 April 2026
The number of companies with Science Based Targets initiative-validated climate goals reached 9,764 by the end of 2025, up 40% from the previous year. Asia added 1,216 companies, nearly matching Europe’s increase. Europe held 49% of validated targets, Asia 36%, and North America 11%. Japan led single markets with 2,091 companies.
Palantir Stock Drops as Michael Burry Says Anthropic Is ‘Eating Its Lunch’

Palantir Stock Drops as Michael Burry Says Anthropic Is ‘Eating Its Lunch’

9 April 2026
Palantir Technologies dropped about 7% Thursday after Michael Burry said Anthropic was overtaking it in enterprise AI, putting Palantir on track to lose $34 billion in market value. Anthropic reported its annualized revenue run rate had surged past $30 billion and launched new AI tools for businesses. Nearly one in four businesses on Ramp now pays for Anthropic, according to Ramp data. Palantir’s stock still trades at 395 times earnings.
Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

9 April 2026
Salesforce shares hit a new 52-week low Thursday, dropping 3.7% to $169.76 despite reporting 12% revenue growth and strong demand for its AI products. The broader software sector continued to slide, with the S&P 500 software and services index down about $1 trillion since January. Salesforce raised its buyback authorization to $50 billion and increased its dividend to 44 cents a share.
ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

9 April 2026
ServiceNow shares dropped 5.1% to $92.45 by 10:20 a.m. EDT Thursday, hitting a new 52-week low after analysts at Stifel, BTIG, and Goldman Sachs cut price targets citing weak federal spending and limited 2026 growth. The company announced it will integrate AI, data, security, and governance into all products ahead of first-quarter results due April 22.
SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

9 April 2026
SoFi Technologies shares fell 1.9% to $16.18 Thursday after KBW and Wells Fargo cut price targets ahead of first-quarter results due April 29. The moves follow Muddy Waters’ short position and claims of accounting issues, which SoFi denies. Affirm and LendingClub also traded lower. Barclays and other banks have trimmed targets as concerns mount over credit quality and sector valuations.
Go toTop